Agenus Inc. (NASDAQ:AGEN - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Agenus in a research note issued on Thursday, December 5th. HC Wainwright analyst E. Bodnar expects that the biotechnology company will earn ($2.29) per share for the quarter. HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Agenus' current full-year earnings is ($12.93) per share. HC Wainwright also issued estimates for Agenus' Q2 2025 earnings at ($1.86) EPS and Q3 2025 earnings at ($1.52) EPS.
Several other analysts have also recently weighed in on AGEN. StockNews.com cut shares of Agenus from a "hold" rating to a "sell" rating in a research note on Monday, August 12th. B. Riley decreased their price target on Agenus from $42.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $10.00.
Check Out Our Latest Stock Report on AGEN
Agenus Price Performance
Shares of AGEN traded up $0.44 during trading hours on Friday, hitting $3.58. The stock had a trading volume of 441,268 shares, compared to its average volume of 742,636. The stock has a market capitalization of $83.98 million, a price-to-earnings ratio of -0.32 and a beta of 1.24. The company's fifty day moving average is $3.98 and its two-hundred day moving average is $7.83. Agenus has a 52 week low of $2.50 and a 52 week high of $19.69.
Hedge Funds Weigh In On Agenus
Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company's stock valued at $19,953,000 after acquiring an additional 4,134,232 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Agenus by 52.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company's stock valued at $208,000 after purchasing an additional 123,058 shares during the period. Federated Hermes Inc. bought a new position in shares of Agenus in the 2nd quarter valued at about $1,921,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Agenus during the 2nd quarter worth approximately $106,000. Finally, Walleye Capital LLC acquired a new stake in shares of Agenus during the 3rd quarter worth approximately $1,003,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Recommended Stories
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
